Re-programming mouse liver-resident invariant natural killer T cells for suppressing hepatic and diabetogenic autoimmunity
Channakeshava Sokke Umeshappa,Patricia Solé,Jun Yamanouchi,Saswat Mohapatra,Bas G. J. Surewaard,Josep Garnica,Santiswarup Singha,Debajyoti Mondal,Elena Cortés-Vicente,Charlotte D’Mello,Andrew Mason,Paul Kubes,Pau Serra,Yang Yang,Pere Santamaria
DOI: https://doi.org/10.1038/s41467-022-30759-w
IF: 16.6
2022-06-07
Nature Communications
Abstract:Abstract Invariant NKT (iNKT) cells comprise a heterogeneous group of non-circulating, tissue-resident T lymphocytes that recognize glycolipids, including alpha-galactosylceramide (αGalCer), in the context of CD1d, but whether peripheral iNKT cell subsets are terminally differentiated remains unclear. Here we show that mouse and human liver-resident αGalCer/CD1d-binding iNKTs largely correspond to a novel Zbtb16 + Tbx21 + Gata3 + Maf low Rorc – subset that exhibits profound transcriptional, phenotypic and functional plasticity. Repetitive in vivo encounters of these liver iNKT (LiNKT) cells with intravenously delivered αGalCer/CD1d-coated nanoparticles (NP) trigger their differentiation into immunoregulatory, IL-10+IL-21-producing Zbtb16 high Maf high Tbx21 + Gata3 + Rorc – cells, termed LiNKTR1, expressing a T regulatory type 1 (TR1)-like transcriptional signature. This response is LiNKT-specific, since neither lung nor splenic tissue-resident iNKT cells from αGalCer/CD1d-NP-treated mice produce IL-10 or IL-21. Additionally, these LiNKTR1 cells suppress autoantigen presentation, and recognize CD1d expressed on conventional B cells to induce IL-10+IL-35-producing regulatory B (Breg) cells, leading to the suppression of liver and pancreas autoimmunity. Our results thus suggest that LiNKT cells are plastic for further functional diversification, with such plasticity potentially targetable for suppressing tissue-specific inflammatory phenomena.
multidisciplinary sciences